Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-014-3248-4
Published Online: 2014-12-24
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tolaney, Sara
Burris, Howard
Gartner, Elaina
Mayer, Ingrid A.
Saura, Cristina
Maurer, Matthew
Ciruelos, Eva
Garcia, Agustin A.
Campana, Frank
Wu, Bin
Xu, Yi
Jiang, Jason
Winer, Eric
Krop, Ian
Text and Data Mining valid from 2014-12-24